Abstract
Background Nivolumab plus standard chemotherapy has significant clinical benefits for unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC). However, nivolumab is expensive, necessitating a cost-effectiveness evaluation. Aim This study aimed to evaluate the cost-effectiveness of nivolumab plus standard chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic GC/GEJC/EAC from the Chinese healthcare system perspective. This study was based on randomized clinical trial data from the CheckMate-649 clinical trial (NCT02872116) published in Lancet (June 2021). Method A Markov model was used to assess the cost-effectiveness of nivolumab plus standard chemotherapy versus chemotherapy alone for unresectable advanced or metastatic GC/GEJC/EAC. Drug costs were collected from Tianjin Medical Purchasing Center in 2021, and utility values of health states were obtained from the literature. The reliability of model was assessed with one-way and probabilistic sensitivity analyses. Main outcome measure The main outcomes were costs, quality-adjusted life-years (QALYs) and the incremental cost-effectiveness ratio (ICER). Results Over a 10-year horizon, the outputs were 1.19 QALYs at a cost of $78,814.9 and 0.88 QALYs at a cost of $19,522.3 with nivolumab plus chemotherapy and chemotherapy alone, respectively. The ICER for nivolumab plus chemotherapy versus chemotherapy alone was $191,266/QALY, exceeding the willingness-to-pay (WTP) threshold ($33,436/QALY). One-way sensitivity analysis revealed nivolumab cost was the most influential parameter. Conclusion Adding nivolumab is not cost-effective for unresectable advanced or metastatic GC/GEJC/EAC in the current Chinese healthcare environment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer. 2019;144(8):1941–53. https://doi.org/10.1002/ijc.31937.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012[J]. Int J Cancer. 2015;136(5):E359-386. https://doi.org/10.1002/ijc.29210.
Gao K, Wu J. National trend of gastric cancer mortality in China (2003–2015): a population-based study[J]. Cancer Commun (Lond). 2019;39(1):24. https://doi.org/10.1186/s40880-019-0372-x.
Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev. 2017;8(8):CD004064.
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet. 2021;398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
Liu GE. China guidelines for pharmacoeconomic evaluations and manual. Beijing: Science Press, 2016: 20-26. ISBN 978-7-03-042153-1.
Tabulation on the 2010 population census of the people‘s republic of China. http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm. Accessed 19 Sep 2021.
http://www.getdata-graph-digitizer.com/index.php. Accessed 19 Sep 2021.
Li S, Peng L, Tan C, et al. Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China[J]. PLoS ONE. 2020;15(5):e0232240. https://doi.org/10.1371/journal.pone.0232240.
Chongqing T, Liubao P, Xiaohui Z, et al. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese national comprehensive cancer network (NCCN) clinical practice guidelines in oncology: gastric cancer[J]. Pharmacoeconomics. 2014;32(3):235–43. https://doi.org/10.1007/s40273-013-0065-2.
Chen HD, Zhou J, Wen F, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer[J]. J Cancer Res Clin Oncol. 2017;143(2):361–8. https://doi.org/10.1007/s00432-016-2296-z.
Wan X, Zhang Y, Tan C, et al. First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis [J]. JAMA Oncol. 2019;5(4):491–6. https://doi.org/10.1001/jamaoncol.2018.7086.
Lin S, Luo S, Zhong L, et al. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer[J]. Int J Clin Pharm. 2020;42(4):1175–83. https://doi.org/10.1007/s11096-020-01076-3.
Jiang Y, Wang X. Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China. Eur J Hosp Pharm. 2020. https://doi.org/10.1136/ejhpharm-2020-002208.
Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J]. Lancet. 2018;392(10142):123–33. https://doi.org/10.1016/S0140-6736(18)31257-1.
Abernero J, Cutsem EV, Bang YJ, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study[J]. J Clin Oncol. 2019;37(18_suppl):LBA4007–LBA4007. https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007.
Moehler M, Dvorkin M, Boku N, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100[J]. J Clin Oncol. 2021;39(9):966–77. https://doi.org/10.1200/JCO.20.00892.
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet. 2017;390(10111):2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5.
Takushima Y, Igarashi A, Yoshihara H, et al. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan[J]. Jpn J Clin Oncol. 2021. https://doi.org/10.1093/jjco/hyab086.
Acknowledgements
We thank the editor and two anonymous referees for their helpful comments.
Funding
No funding was received for conducting this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
All authors declare that they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Jiang, Y., Li, Y. & Wang, L.X.W. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Int J Clin Pharm 44, 499–506 (2022). https://doi.org/10.1007/s11096-021-01372-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-021-01372-6